|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,235,169: Dexketoprofen Trometamol
U.S. Patent 11,235,169, titled "Dexketoprofen trometamol drug substance and process for preparing the same," was granted on January 25, 2022. This patent covers a specific pharmaceutical composition and a manufacturing process for dexketoprofen trometamol. Dexketoprofen trometamol is the tromethamine salt of dexketoprofen, a nonsteroidal anti-inflammatory drug (NSAID). The patent's claims focus on the crystalline form of dexketoprofen trometamol, its purity, and a method for its synthesis. The granted claims provide a basis for market exclusivity, impacting generic competition and the commercialization of this drug substance.
What is the Core Invention of U.S. Patent 11,235,169?
The primary invention described in U.S. Patent 11,235,169 is a specific crystalline form of dexketoprofen trometamol, designated as Form I. This crystalline form is characterized by particular X-ray diffraction (XRD) patterns and other physicochemical properties that distinguish it from other potential polymorphic forms of the same chemical compound. The patent also claims a process for preparing this specific crystalline form with controlled purity.
- Claim 1: Claims a crystalline form of dexketoprofen trometamol, referred to as Form I, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four specific diffraction peaks at defined 2-theta angles. These peaks are at 6.6 ± 0.2°, 13.3 ± 0.2°, 17.4 ± 0.2°, and 22.6 ± 0.2°. This precise XRPD fingerprint is central to defining the claimed crystalline form.
- Claim 2: Claims crystalline Form I of dexketoprofen trometamol as defined in claim 1, further characterized by an XRPD pattern comprising additional specific diffraction peaks. This expands the XRPD definition, providing further specificity to the claimed form.
- Claim 3: Claims crystalline Form I of dexketoprofen trometamol as defined in claim 1, further characterized by an XRPD pattern comprising a total of seven specific diffraction peaks, including peaks at 6.6 ± 0.2°, 13.3 ± 0.2°, 17.4 ± 0.2°, 22.6 ± 0.2°, 24.1 ± 0.2°, 25.7 ± 0.2°, and 29.3 ± 0.2°. This provides a more comprehensive XRPD profile for the claimed substance.
- Claim 4: Claims crystalline Form I of dexketoprofen trometamol as defined in claim 1, characterized by a differential scanning calorimetry (DSC) curve comprising a specific endothermic peak with a melting onset temperature of approximately 127°C. This thermal property adds another layer of characterization for the patented form.
- Claim 5: Claims crystalline Form I of dexketoprofen trometamol as defined in claim 1, characterized by a Fourier transform infrared (FT-IR) spectrum comprising specific absorption bands at particular wavenumbers. This spectroscopic data provides further means to identify and distinguish the claimed crystalline form.
- Claim 6: Claims crystalline Form I of dexketoprofen trometamol as defined in claim 1, having a purity of not less than 99.5% by weight of dexketoprofen trometamol. This purity threshold is a critical aspect of the claimed substance, particularly for pharmaceutical applications.
- Claim 7: Claims a process for preparing crystalline Form I of dexketoprofen trometamol, comprising: (a) dissolving dexketoprofen and trometamol in a solvent or a mixture of solvents; (b) inducing crystallization of dexketoprofen trometamol by cooling; and (c) isolating the crystalline dexketoprofen trometamol. This claim outlines a general method for producing the patented form.
- Claim 8: Claims the process of claim 7, wherein the solvent or mixture of solvents comprises an alcohol and water. This specifies the types of solvents used in the claimed process, narrowing the scope of the manufacturing method.
- Claim 9: Claims the process of claim 8, wherein the alcohol is isopropanol. This further refines the solvent composition by specifying isopropanol as a key component.
- Claim 10: Claims the process of claim 7, wherein the temperature of cooling is between 20°C and 0°C. This defines the cooling parameters for inducing crystallization, contributing to the control of the crystalline form.
- Claim 11: Claims the process of claim 7, further comprising seeding the solution with crystals of dexketoprofen trometamol. This describes a technique for controlling crystal growth and morphology, likely aimed at producing Form I.
The patent's claims define specific physicochemical properties, including XRPD peaks, DSC thermal data, FT-IR spectra, and purity levels, to characterize the claimed crystalline form. The process claims detail steps for producing this form, including solvent selection and crystallization conditions.
What is the Patent Landscape for Dexketoprofen Trometamol?
The patent landscape for dexketoprofen trometamol is characterized by existing patents covering the active pharmaceutical ingredient (API) itself, its various salt forms, and different polymorphic forms, as well as manufacturing processes and pharmaceutical compositions. U.S. Patent 11,235,169 adds to this landscape by focusing on a specific crystalline form (Form I) and its preparation.
- Core Compound Patents: The initial patents covering dexketoprofen and its salts, including trometamol, would have expired or are nearing expiration, allowing for generic development. However, new patents can claim novel forms or improved processes.
- Polymorph Patents: The existence of U.S. Patent 11,235,169 highlights the strategy of patenting specific crystalline (polymorphic) forms of a drug. Different polymorphs can exhibit different physical properties such as solubility, stability, and bioavailability, which can be patentable if they offer a demonstrable advantage.
- Process Patents: Patents claiming novel or improved manufacturing processes are common. U.S. Patent 11,235,169 includes claims directed to a process for preparing crystalline Form I. These process patents can create additional barriers to entry for generic manufacturers, even if the core compound patent has expired, by requiring them to avoid the patented process.
- Formulation Patents: Patents may also cover specific pharmaceutical formulations (e.g., tablets, capsules, injectables) containing dexketoprofen trometamol, which might offer advantages in delivery or efficacy.
- Orphan Drug Designations and Exclusivities: While not a patent, regulatory exclusivities (e.g., for orphan drugs, new chemical entities) can also provide market protection. Dexketoprofen trometamol is not generally considered an orphan drug, so its market exclusivity is primarily driven by patents.
A thorough Freedom-to-Operate (FTO) analysis would be required to determine if a generic version or a new formulation infringes on any active patents, including U.S. Patent 11,235,169. This analysis would involve searching for other patents related to dexketoprofen trometamol, its polymorphs, processes, and formulations, and assessing their validity and scope.
How Does U.S. Patent 11,235,169 Impact Generic Competition?
U.S. Patent 11,235,169, by claiming a specific crystalline form (Form I) and a process for its preparation, has the potential to influence generic competition. The impact depends on several factors, including the patent's remaining term, the enforceability of its claims, and the availability of alternative crystalline forms or manufacturing processes.
- Exclusivity for Form I: The patent grants exclusive rights to make, use, and sell dexketoprofen trometamol in crystalline Form I as defined in the claims. Generic manufacturers seeking to market a product containing this specific crystalline form would need to await the patent's expiration or obtain a license.
- Process Restrictions: The process claims can prevent generic manufacturers from using the patented method to produce Form I. If the patented process offers significant advantages in terms of yield, purity, or cost-effectiveness, it could be a crucial barrier. Generic companies would need to develop non-infringing processes, which might be less efficient or more costly.
- Polymorphic Alternatives: Generic companies may attempt to develop and patent alternative crystalline forms of dexketoprofen trometamol that do not infringe on the claims of U.S. Patent 11,235,169. If such alternative forms offer comparable or superior properties and can be manufactured efficiently, they could become viable options for generic products after the expiration of earlier patents on the compound itself.
- Litigation Risk: If a generic company launches a product that a patent holder believes infringes on U.S. Patent 11,235,169, litigation could ensue. The strength of the patent claims, particularly the distinctiveness of Form I based on its XRPD, DSC, and FT-IR characteristics, would be central to any legal challenge.
- Patent Term: The effective lifespan of the patent protection for Form I is determined by its grant date (January 25, 2022) and its expiration date. While U.S. patents generally have a term of 20 years from the filing date, patent term adjustments (PTA) and extensions (PTE) can alter the actual expiry date. A detailed examination of these factors is necessary to determine the precise end of exclusivity.
What Are the Key Characterization Data Presented in the Patent?
U.S. Patent 11,235,169 relies on specific analytical techniques to define and characterize the claimed crystalline Form I of dexketoprofen trometamol. These data points are critical for establishing the novelty and non-obviousness of the claimed invention and for distinguishing it from other forms.
- X-Ray Powder Diffraction (XRPD): The patent provides detailed XRPD data, specifying key diffraction peaks (2-theta values) that are characteristic of Form I. This is a primary method for identifying and differentiating crystalline polymorphs.
- Key peaks cited: 6.6 ± 0.2°, 13.3 ± 0.2°, 17.4 ± 0.2°, 22.6 ± 0.2°, 24.1 ± 0.2°, 25.7 ± 0.2°, and 29.3 ± 0.2°.
- Differential Scanning Calorimetry (DSC): DSC data is used to characterize the thermal behavior of the crystalline form, particularly its melting point.
- Key characteristic: An endothermic peak with a melting onset temperature of approximately 127°C.
- Fourier Transform Infrared (FT-IR) Spectroscopy: FT-IR provides a molecular fingerprint of the compound, identifying functional groups and their vibrations.
- The patent references specific absorption bands in the FT-IR spectrum as characteristic of Form I, though the exact wavenumbers are detailed within the patent document itself.
- Purity Analysis: The patent specifies a minimum purity requirement for the claimed crystalline form.
- Purity: Not less than 99.5% by weight of dexketoprofen trometamol.
These characterization data points collectively define the scope of protection for crystalline Form I, ensuring that only material meeting these specific criteria is covered by the patent.
What are the Claims Related to the Manufacturing Process?
U.S. Patent 11,235,169 includes claims directed to a specific process for preparing crystalline Form I of dexketoprofen trometamol. These claims are designed to protect the method of manufacture, which can be as important as the product itself in terms of market exclusivity.
- General Process (Claim 7): The core process involves:
- Dissolving dexketoprofen and trometamol in a solvent or mixture of solvents.
- Inducing crystallization of dexketoprofen trometamol by cooling.
- Isolating the crystalline dexketoprofen trometamol.
- Solvent Specification (Claim 8): The patent specifies that the solvent system comprises an alcohol and water. This combination is common in API crystallization to control solubility and crystal habit.
- Specific Alcohol (Claim 9): Further refinement is provided by specifying isopropanol as the alcohol component in the solvent mixture.
- Cooling Parameters (Claim 10): The process involves cooling the solution to a temperature range between 20°C and 0°C to induce crystallization. Precise temperature control is often critical for achieving a specific polymorphic form.
- Seeding (Claim 11): The process may optionally include seeding the solution with pre-existing crystals of dexketoprofen trometamol. Seeding is a technique used to control the nucleation and growth of crystals, often employed to ensure the formation of a desired polymorphic form.
These process claims provide a specific pathway to produce the patented crystalline Form I. Generic manufacturers must ensure their manufacturing processes do not infringe on these claims.
What is the Commercial Significance of Crystalline Forms?
The patenting of specific crystalline forms, or polymorphs, is a well-established strategy in the pharmaceutical industry to extend market exclusivity beyond the expiration of the original compound patent. The commercial significance of crystalline forms stems from their ability to influence critical drug properties.
- Bioavailability and Efficacy: Different polymorphs can have varying solubilities and dissolution rates, directly impacting the bioavailability of a drug. A more soluble or faster-dissolving form can lead to improved therapeutic efficacy and potentially a faster onset of action.
- Stability: Polymorphs can differ in their physical and chemical stability. Some forms may be more prone to degradation or conversion to less desirable forms under storage conditions, affecting shelf life and product quality.
- Manufacturing and Formulation: The physical characteristics of a crystalline form, such as particle size, shape, and flowability, can significantly affect its processability during manufacturing (e.g., tableting, encapsulation). A consistently manufacturable form is commercially advantageous.
- Intellectual Property Protection: By patenting a specific crystalline form that exhibits advantageous properties or is produced by a novel process, pharmaceutical companies can create new barriers to generic competition. This is particularly relevant when the patent on the active pharmaceutical ingredient (API) itself is close to expiring.
- Regulatory Considerations: Regulatory agencies like the FDA require detailed characterization of the crystalline form of an API. Identifying and controlling the specific polymorph is crucial for ensuring consistent product quality and therapeutic equivalence.
U.S. Patent 11,235,169 leverages this strategy by defining and claiming a specific crystalline form of dexketoprofen trometamol, Form I, along with its characteristic properties and a method for its preparation.
Key Takeaways
- U.S. Patent 11,235,169 protects a specific crystalline form of dexketoprofen trometamol, designated as Form I, characterized by unique X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) data, and Fourier transform infrared (FT-IR) spectra.
- The patent also claims a manufacturing process for this crystalline form, involving the dissolution of dexketoprofen and trometamol in a solvent mixture (alcohol and water, specifically isopropanol and water), cooling between 20°C and 0°C, and potentially seeding.
- This patent can extend market exclusivity for dexketoprofen trometamol by preventing generic manufacturers from producing or selling Form I until the patent expires, unless they obtain a license or develop non-infringing crystalline forms or processes.
- The claimed purity for Form I is not less than 99.5% by weight.
- The commercial significance of crystalline forms lies in their impact on drug properties such as bioavailability, stability, and manufacturability, making them key targets for intellectual property protection in the pharmaceutical industry.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 11,235,169?
U.S. patents typically have a term of 20 years from the filing date. The expiration date would depend on the patent's filing date and any applicable patent term adjustments or extensions. A precise expiry date requires consulting the official USPTO patent record.
-
Does U.S. Patent 11,235,169 cover all forms of dexketoprofen trometamol?
No, the patent specifically claims a particular crystalline form, Form I, and a process for its preparation. Other crystalline forms or amorphous forms of dexketoprofen trometamol may not be covered by this patent, provided they do not infringe on any other active patents.
-
Can generic manufacturers use dexketoprofen trometamol if they develop a different manufacturing process?
Generic manufacturers can develop alternative manufacturing processes. However, they must ensure their process does not infringe on the claims of U.S. Patent 11,235,169 or any other active patents covering dexketoprofen trometamol. If the alternative process produces a crystalline form covered by the patent, it would still be infringing.
-
What is the significance of the specified XRPD peaks in the patent claims?
The specified X-ray powder diffraction (XRPD) peaks are unique identifiers for crystalline Form I. They serve as definitive evidence to distinguish this specific crystalline structure from other potential polymorphic forms of dexketoprofen trometamol, forming a core part of the patent's claims for novelty and non-obviousness.
-
Does this patent prevent the use of dexketoprofen trometamol for any medical indications?
This patent covers the specific crystalline form and its manufacturing process, not the medical indications for which dexketoprofen trometamol may be used. The use of dexketoprofen trometamol for approved medical indications would be restricted only if it involves the patented crystalline form or process, and the patent is still in force.
Citations
[1] United States Patent 11,235,169. (2022). Dexketoprofen trometamol drug substance and process for preparing the same. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
